Clinical trial · Observational
MELT - MRI Evaluation of Lymphoma Treatment
Whole Body Functional and Anatomical MRI: Accuracy in Staging and Treatment Response Monitoring in Adolescent Hodgkin's Lymphoma Compared to Conventional Multimodality Imaging
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Patients who are newly diagnosed with Hodgkin's lymphoma will undergo disease staging at diagnosis and initial treatment response assessment. At each time point (initial staging and treatment response assessment) in addition to standard imaging investigations (PET CT, Chest CT, anatomical MRI of the abdomen and pelvis and abdominal USS), patients will undergo an extended MRI scan.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Lymphoma, Hodgkin | Hodgkin Lymphoma | ONTOLOGY_EXACT | 0.90 |
Interventions
Interventions (0)
Data not yet available
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- The per site sensitivity and specificity of MRI for both nodal and extranodal sites and concordance in final disease stage with the multi-modality reference standard
- timeFrame
- The recruited patients to be followed up for 1 year
Secondary outcomes (5)
- measure
- The number of correct patient classifications into therapy responders and non-responders by MRI compared to the multi modality reference
- timeFrame
- The recruited patients to be followed up for 1 year
- measure
- Inter observer agreement for MRI between reporting radiologists (on site and off site). responders by MRI compared to the multi modality reference
- timeFrame
- The recruited patients to be followed up for 1 year
- measure
- Sensitivity, specificity of qualitative assessment of Minimum intensity projection (MIP) inverted high B value datasets
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 5 Years
- Maximum age
- 20 Years
Show eligibility criteria text
Inclusion Criteria: * Aged 5 to 20 years (inclusive) with participant and parent/guardian informed consent * Histologically confirmed first presentation of Hodgkin's Lymphoma * Either entered into the Euronet PHL-C1 trial or LP1 trials OR not formally entered into the Euronet trials but treated on the chemotherapy regimens of the Euronet trials for classical and lymphocyte predominant Hodgkin Lymphoma Exclusion Criteria: * Contraindications to MRI (e.g. pacemaker) * Previous malignancy or previous chemotherapy or radiotherapy treatment for malignancy * Pregnancy or nursing
References
Publications (0)
Data not yet available